<DOC>
	<DOCNO>NCT02099656</DOCNO>
	<brief_summary>This Phase II , randomize , double-blind , placebo-controlled , multicenter study evaluate effect lebrikizumab airway eosinophilic inflammation participant uncontrolled asthma use inhale corticosteroid ( ICS ) treatment second controller medication . Enrolled participant undergo 3-week screening period assessment , include bronchoscopy procedure , make . Participants subsequently randomize receive lebrikizumab placebo subcutaneous ( SC ) injection Day 1 , Day 8 , Week 4 , Week 8 . Participants continue standard care therapy throughout study . End treatment assessment take Week 12 . Total study period , include screen follow-up , expect last 23 week .</brief_summary>
	<brief_title>A Study Evaluating Effects Lebrikizumab Airway Eosinophilic Inflammation Participants With Uncontrolled Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Asthma diagnosis great equal ( &gt; /= ) 12 month prior Visit 1 Bronchodilator response demonstrate within 12 month Visit 1 Visit 1 , 2 , 3 screen Prebronchodilator FEV1 40 percent ( % ) 80 % predict Visits 2 3 On ICS therapy total daily dose 5002000 mcg fluticasone propionate dry powder inhaler ( DPI ) equivalent &gt; /= 6 month prior Visit 1 , change within 4 week prior Visit 1 , anticipate change throughout study On eligible second controller medication ( longacting Betaagonist [ LABA ) , leukotriene receptor antagonist [ LTRA ] , longacting muscarinic antagonist [ LAMAs ] theophylline ) 6 month prior Visit 1 , change within 4 week prior Visit 1 , anticipate change throughout study Uncontrolled asthma Visit 1 and/or 2 Visit 3 Chest Xray compute tomography ( CT ) scan within 12 month prior Visit 1 chest Xray screen period ( prior Visit 3 ) confirms absence clinically significant lung disease Demonstrated adherence controller medication screen period Maintenance oral corticosteroid therapy , define daily alternateday oral corticosteroid maintenance therapy within 3 month prior Visit 1 Treatment systemic corticosteroid within 4 week prior Visit 1 screen period reason , include acute exacerbation event Any infection require hospital , intravenous ( IV ) intramuscular ( IM ) antibiotic treatment respiratory infection within 4 week prior Visit 1 screening . Any infection require oral antibiotic treatment 2 week prior Visit 1 screening , parasitic infection within 6 month prior Visit 1 screen Active tuberculosis require treatment within 12 month prior Visit 1 Known immunodeficiency , include , limited , human immunodeficiency virus ( HIV ) infection History interstitial lung disease , chronic obstructive pulmonary disease ( COPD ) , clinically significant lung disease asthma Known current malignancy current evaluation potential malignancy Unable safely undergo elective flexible fiberoptic bronchoscopy Clinically significant medical disease uncontrolled despite treatment , likely , opinion investigator , impact participant 's ability participate study , impact study assessment History alcohol drug abuse would impair risk participant 's full participation study , opinion investigator Current smoker history smoking ( great [ &gt; ] 10 packyears ) , unwillingness abstain smoking duration study Past and/or current use antiinterleukin ( IL ) 13 antiIL4/IL13 therapy , include lebrikizumab Use license investigational monoclonal antibody antiIL13 , anti IL4/IL13 , include , limited , omalizumab , antiIL5 , antiIL17 , within 6 month 5 drug halflives prior Visit 1 ( whichever longer ) screen Use systemic immunomodulatory immunosuppressive therapy within 3 month 5 drug halflives prior Visit 1 ( whichever longer ) screen Use investigational therapy within 4 week 5 drug halflives prior Visit 1 ( whichever longer ) screen Initiation increase allergen immunotherapy within 3 month prior Visit 1 screen Body mass index &gt; 38 kilogram per square meter ( kg/m^2 ) Body weight &lt; 40 kilogram ( kg ) History bronchial thermoplasty</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>